Search Main Menu Main Content

Choose language
Change contrast :
Standards Reinforced

icone

HAS profile

Mission
Organisational Structure
Ethics, transparency and management of conflicts of interest

International relations and projects
Publications

Recherche

icone plus
My account

Email alert Subscription

Newsletter Subscription

My search

Refresh

Please fill in your email address to retrieve your email alerts subscriptions.

New subscription

Please fill in your email address to retrieve your newsletter subscriptions.

You do not have a saved search
No element in selection
Contact

1 result

Language : Français
Active substance : eltrombopag
Active substance : azacitidine
Topics : Blood and lymphatic diseases

Topic

Diseases and conditions (1)
Plus ...
- Blood and lymphatic diseases (1)
- Plus ...
  - Bone marrow diseases (1)

Practice Guidelines and Other Guides (1)
Plus ...
- Chronic disease guide (1)

Date

Last five years (1)

Français (1)

Active substance

azacitidine (1)
ciprofloxacine (1)
eltrombopag (1)
fer (1)
romiplostim (1)

Practice guidelines and other guides - 1 result

Bone marrow failures and other chronic cytopenias myelodysplastic syndromes

Chronic disease guide - Posted on 20/11/2018

Download guide

Add to my selection

Advancing quality in the fields of health and social care services

Follow us :

Eunetha.eu
Pasq.eu

All our publications by topic and type

Opinions on medicines
Opinions on medical devices
INAHTA briefs

Français
English

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

DGBtxLPwasxHFeKk